vs
Beachbody Company, Inc.（BODI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Beachbody Company, Inc.的1.3倍（$69.8M vs $55.5M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 9.4%，领先374.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -35.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -32.0%）
比奇博迪公司是总部位于美国加利福尼亚州埃尔塞贡多的上市健康健身企业，主打健身课程方案、营养产品与膳食补剂销售，1998年成立，凭借P90X、Insanity两款知名健身课程在行业内建立了知名度。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
BODI vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.3倍
$55.5M
营收增速更快
RIGL
高出56.9%
-35.7%
净利率更高
RIGL
高出374.6%
9.4%
两年增速更快
RIGL
近两年复合增速
-32.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.5M | $69.8M |
| 净利润 | $5.2M | $268.1M |
| 毛利率 | 74.5% | 91.5% |
| 营业利润率 | 14.7% | 33.2% |
| 净利率 | 9.4% | 384.0% |
| 营收同比 | -35.7% | 21.2% |
| 净利润同比 | 115.1% | 1769.2% |
| 每股收益（稀释后） | $0.77 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BODIRIGL
| Q4 25 | $55.5M | $69.8M | ||
| Q3 25 | $59.9M | $69.5M | ||
| Q2 25 | $63.9M | $101.7M | ||
| Q1 25 | $72.4M | $53.3M | ||
| Q4 24 | $86.4M | $57.6M | ||
| Q3 24 | $102.2M | $55.3M | ||
| Q2 24 | $110.2M | $36.8M | ||
| Q1 24 | $120.0M | $29.5M |
净利润BODIRIGL
| Q4 25 | $5.2M | $268.1M | ||
| Q3 25 | $3.6M | $27.9M | ||
| Q2 25 | $-5.9M | $59.6M | ||
| Q1 25 | $-5.7M | $11.4M | ||
| Q4 24 | $-34.6M | $14.3M | ||
| Q3 24 | $-12.0M | $12.4M | ||
| Q2 24 | $-10.9M | $-1.0M | ||
| Q1 24 | $-14.2M | $-8.2M |
毛利率BODIRIGL
| Q4 25 | 74.5% | 91.5% | ||
| Q3 25 | 74.6% | 93.2% | ||
| Q2 25 | 72.3% | 95.6% | ||
| Q1 25 | 71.2% | 91.7% | ||
| Q4 24 | 70.5% | 89.9% | ||
| Q3 24 | 67.3% | 85.5% | ||
| Q2 24 | 69.3% | 92.4% | ||
| Q1 24 | 67.7% | 93.1% |
营业利润率BODIRIGL
| Q4 25 | 14.7% | 33.2% | ||
| Q3 25 | 8.3% | 40.9% | ||
| Q2 25 | -6.2% | 60.1% | ||
| Q1 25 | -5.1% | 23.9% | ||
| Q4 24 | -38.1% | 28.9% | ||
| Q3 24 | -12.7% | 25.4% | ||
| Q2 24 | -8.6% | 1.2% | ||
| Q1 24 | -9.0% | -23.6% |
净利率BODIRIGL
| Q4 25 | 9.4% | 384.0% | ||
| Q3 25 | 6.0% | 40.2% | ||
| Q2 25 | -9.2% | 58.6% | ||
| Q1 25 | -7.9% | 21.5% | ||
| Q4 24 | -40.0% | 24.9% | ||
| Q3 24 | -11.7% | 22.5% | ||
| Q2 24 | -9.9% | -2.8% | ||
| Q1 24 | -11.8% | -27.9% |
每股收益（稀释后）BODIRIGL
| Q4 25 | $0.77 | $14.11 | ||
| Q3 25 | $0.51 | $1.46 | ||
| Q2 25 | $-0.85 | $3.28 | ||
| Q1 25 | $-0.84 | $0.63 | ||
| Q4 24 | $-5.07 | $0.82 | ||
| Q3 24 | $-1.75 | $0.70 | ||
| Q2 24 | $-1.59 | $-0.06 | ||
| Q1 24 | $-2.10 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.0M | $155.0M |
| 总债务越低越好 | $25.0M | $52.5M |
| 股东权益账面价值 | $31.3M | $391.5M |
| 总资产 | $147.0M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.80× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资BODIRIGL
| Q4 25 | $39.0M | $155.0M | ||
| Q3 25 | $33.9M | $137.1M | ||
| Q2 25 | $25.6M | $108.4M | ||
| Q1 25 | $18.1M | $77.1M | ||
| Q4 24 | $20.2M | $77.3M | ||
| Q3 24 | $32.3M | $61.1M | ||
| Q2 24 | $32.3M | $49.1M | ||
| Q1 24 | $38.9M | $49.5M |
总债务BODIRIGL
| Q4 25 | $25.0M | $52.5M | ||
| Q3 25 | $25.0M | $60.0M | ||
| Q2 25 | $25.0M | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $21.6M | $60.0M | ||
| Q3 24 | $25.2M | $60.0M | ||
| Q2 24 | $24.5M | $60.0M | ||
| Q1 24 | $28.3M | $60.0M |
股东权益BODIRIGL
| Q4 25 | $31.3M | $391.5M | ||
| Q3 25 | $24.7M | $117.6M | ||
| Q2 25 | $20.2M | $81.9M | ||
| Q1 25 | $24.0M | $18.6M | ||
| Q4 24 | $28.2M | $3.3M | ||
| Q3 24 | $58.4M | $-14.6M | ||
| Q2 24 | $66.8M | $-29.9M | ||
| Q1 24 | $72.7M | $-31.7M |
总资产BODIRIGL
| Q4 25 | $147.0M | $513.6M | ||
| Q3 25 | $146.4M | $242.5M | ||
| Q2 25 | $145.9M | $206.7M | ||
| Q1 25 | $152.5M | $176.0M | ||
| Q4 24 | $174.6M | $164.0M | ||
| Q3 24 | $225.5M | $139.4M | ||
| Q2 24 | $245.0M | $128.4M | ||
| Q1 24 | $263.0M | $126.5M |
负债/权益比BODIRIGL
| Q4 25 | 0.80× | 0.13× | ||
| Q3 25 | 1.01× | 0.51× | ||
| Q2 25 | 1.24× | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.77× | 18.25× | ||
| Q3 24 | 0.43× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.39× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $4.3M | — |
| 自由现金流率自由现金流/营收 | 7.7% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | 0.95× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $17.4M | — |
8季度趋势，按日历期对齐
经营现金流BODIRIGL
| Q4 25 | $5.0M | $22.0M | ||
| Q3 25 | $10.2M | $24.0M | ||
| Q2 25 | $4.2M | $30.5M | ||
| Q1 25 | $2.3M | $-893.0K | ||
| Q4 24 | $-6.7M | $14.5M | ||
| Q3 24 | $1.1M | $21.7M | ||
| Q2 24 | $-925.0K | $302.0K | ||
| Q1 24 | $9.1M | $-5.0M |
自由现金流BODIRIGL
| Q4 25 | $4.3M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $2.4M | — | ||
| Q1 25 | $1.6M | — | ||
| Q4 24 | $-7.3M | — | ||
| Q3 24 | $53.0K | — | ||
| Q2 24 | $-2.2M | — | ||
| Q1 24 | $7.4M | — |
自由现金流率BODIRIGL
| Q4 25 | 7.7% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | -8.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | -2.0% | — | ||
| Q1 24 | 6.2% | — |
资本支出强度BODIRIGL
| Q4 25 | 1.3% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.4% | — |
现金转化率BODIRIGL
| Q4 25 | 0.95× | 0.08× | ||
| Q3 25 | 2.85× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BODI
| Digital | $34.3M | 62% |
| Nutrition And Other | $21.2M | 38% |
RIGL
暂无分部数据
